Scientific deep-dive

Retatrutide vs Wegovy: cross-trial weight-loss + safety evidence (2026)

Retatrutide (investigational) -25.0% TBWL at 12 mg / 80 wk in TRIUMPH-1 vs Wegovy (FDA-approved 2021) -14.9% at 68 wk in STEP-1, about 1.7x on a cross-trial basis. No head-to-head RCT. Wegovy has SELECT (20% MACE reduction); retatrutide's outcomes trial is ongoing.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
12 min read·15 citations

The honest answer: Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management since 2021 and for cardiovascular-event reduction since 2024. Retatrutide (Eli Lilly LY3437943) is investigational — its TRIUMPH-1 and TRIUMPH-2 Phase 3 trials are now published (NEJM and Lancet, 2026), and Lilly plans to submit a Biologics License Application to the FDA in the first quarter of 2027[12][13][14]. No head-to-head RCT exists; the magnitude comparison below is cross-trial.

At a glance

  • Wegovy: FDA-approved June 2021 (chronic weight management); cardiovascular-event-reduction indication added March 2024 per SELECT[9][11].
  • Retatrutide: investigational; no FDA approval as of October 2026; Biologics License Application planned for Q1 2027[14].
  • Weight loss (cross-trial): retatrutide 12 mg -25.0% TBWL at 80 wk in TRIUMPH-1 (NEJM, intention-to-treat)[12] vs semaglutide 2.4 mg -14.9% TBWL at 68 wk in STEP-1[6] — roughly 1.7x the Wegovy magnitude. Lilly's earlier press release reported -28.3%[1].
  • Phase 2 retatrutide: Jastreboff 2023 NEJM reported ~24% TBWL at 12 mg / 48 wk (n=338)[3].
  • Mechanism: Wegovy is single-class (GLP-1 only); retatrutide is triple-class (GIP + GLP-1 + glucagon).
  • Cardiovascular outcomes: Wegovy has SELECT (20% relative MACE reduction; HR 0.80)[9]. Retatrutide cardiovascular outcomes trial (TRIUMPH-Outcomes) ongoing[15].
  • Cost today: Wegovy WAC ~$1,349/28 days; NovoCare direct-pay tiers $349 pen / $399 high-dose pen / $149 oral pill (1.5 mg). Retatrutide not commercially available.

Approval status — Wegovy FDA-approved 2021, retatrutide investigational

Wegovy (semaglutide 2.4 mg subcutaneous weekly) received FDA approval for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity on June 4, 2021. In December 2022 the indication was extended to adolescents aged 12 and older. In March 2024 the FDA added a cardiovascular-event-reduction indication based on SELECT (Lincoff 2023 NEJM) for adults with established cardiovascular disease and obesity or overweight, irrespective of diabetes status[9][11]. As of the May 2026 DailyMed label revision, the Section 1 indications, Section 5 warnings, and Section 6.1 clinical trials adverse-reaction table are all in place[11].

Retatrutide remains investigational. Eli Lilly reported TRIUMPH-1 topline results in May 2026 via a PR Newswire investor release and a late-breaking presentation at the 86th American Diabetes Association Scientific Sessions[1][2]. The peer-reviewed TRIUMPH-1 paper followed in NEJM in September 2026; it reports mean weight change at 80 weeks of -17.6% (4 mg), -23.7% (9 mg), and -25.0% (12 mg) versus -3.9% on placebo under the treatment-regimen (intention-to-treat) estimand[12]. The tables below use these published figures; Lilly's earlier press release reported higher numbers (-28.3% at 12 mg). Lilly's August 2026 earnings release says it plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027[14]; it has not announced a US brand name. For broader context on the molecule, see our retatrutide triple agonist evidence review.

Weight loss head-to-head data

There is no head-to-head RCT of retatrutide vs semaglutide 2.4 mg. What follows is cross-trial: TRIUMPH-1 (retatrutide, n=2,339, 80 weeks)[1][2] compared with STEP-1 (semaglutide 2.4 mg, n=1,961, 68 weeks)[6]. Trial populations and lifestyle interventions differ; the comparison is informative but not RCT-grade. Verified mean total body-weight reduction (TBWL):

ArmMean TBWLEndpointSource
Retatrutide 12 mg (TRIUMPH-1 extension, BMI 35+)-30.3%104 wkLilly PR + ADA 86th[1]
Retatrutide 12 mg (TRIUMPH-1)-25.0%80 wkNEJM 2026 PMID 42814954[12]
Retatrutide 9 mg (TRIUMPH-1)-23.7%80 wkNEJM 2026 PMID 42814954[12]
Retatrutide 12 mg (Phase 2, Jastreboff 2023)~-24.2%48 wkNEJM PMID 37366315[3]
Retatrutide 4 mg (TRIUMPH-1)-17.6%80 wkNEJM 2026 PMID 42814954[12]
Wegovy semaglutide 2.4 mg (STEP-1)-14.9%68 wkNEJM PMID 33567185[6]
Placebo (STEP-1)-2.4%68 wkNEJM PMID 33567185[6]
Placebo (TRIUMPH-1)-3.9%80 wkNEJM 2026 PMID 42814954[12]

Cross-trial, retatrutide 12 mg at 80 weeks (-25.0% in the published NEJM intention-to-treat analysis[12]) is approximately 1.7x larger than Wegovy 2.4 mg at 68 weeks (-14.9%)[6]. Even the retatrutide 4 mg dose (-17.6%) exceeds the Wegovy 2.4 mg STEP-1 result. Lilly's press release reported a 104-week BMI-35+ extension reaching -30.3% TBWL[1], a magnitude historically associated with bariatric surgery. For the deeper TRIUMPH-1 dose-response breakdown plus responder rates, see our retatrutide TRIUMPH-1 before-and-after evidence article. For the within-Wegovy comparison to Ozempic, see our Wegovy vs Ozempic evidence review.

Mechanism — triple-class (GIP + GLP-1 + glucagon) vs single-class (GLP-1 only)

Wegovy is semaglutide, a long-acting GLP-1 receptor agonist. The single receptor mechanism drives satiety, slowed gastric emptying, and glucose-dependent insulin secretion — the established GLP-1 class effects underlying its 14.9% STEP-1 result[6].

Retatrutide engages three receptors:

  • GLP-1 receptor — same satiety + gastric-emptying axis as semaglutide.
  • GIP receptor — adipose and insulin-sensitizing axis (the same target tirzepatide uses in addition to GLP-1).
  • Glucagon receptor — adds hepatic energy expenditure and lipolysis, the mechanism most cited as the source of the additional magnitude vs dual GIP/GLP-1 agents.

The Phase 2 trial (Jastreboff 2023 NEJM, PMID 37366315)[3] established proof-of-concept: retatrutide 12 mg produced approximately 24.2% TBWL at 48 weeks in 338 randomized adults with obesity (no T2D). Pearson 2026 JCEM[5] reported the lipid and metabolite secondary analysis consistent with the glucagon-receptor-driven hepatic-energy mechanism.

Trial duration + populations differ — caveats

Cross-trial comparison is informative but not RCT-grade. Important differences:

  • Endpoint timing: TRIUMPH-1 primary endpoint at 80 weeks[1]; STEP-1 primary endpoint at 68 weeks[6]. Longer treatment generally yields more loss; an 80-week vs 68-week comparison advantages retatrutide somewhat by duration alone.
  • Baseline characteristics: STEP-1 enrolled adults with BMI 30+ (or 27+ with weight-related comorbidity), no T2D[6]. TRIUMPH-1 enrolled a similar population, and its baseline characteristics are reported in the full NEJM paper[12].
  • Lifestyle intervention: both trials provided structured caloric reduction and physical-activity counseling; placebo arms lost 2.4% in STEP-1[6] and 3.9% in TRIUMPH-1[12].
  • Citation rigor: STEP-1 is a published NEJM paper with full safety tables; TRIUMPH-1 is now published in NEJM[12], and the dose-level figures in this article use the paper's intention-to-treat results; the nausea figure still comes from Lilly's press release.

For T2D-specific cross-trial framing, the STEP-2 trial (Davies 2021 Lancet, PMID 33667417)[7] reported semaglutide 2.4 mg produced -9.6% TBWL at 68 weeks in adults with T2D, smaller than the non-diabetic STEP-1 cohort. TRIUMPH-2 (retatrutide in T2D, Lancet 2026) reported -16.8% (9 mg) and -18.8% (12 mg) at 80 weeks versus -5.1% on placebo[13]. Cross-trial, with different durations and no head-to-head RCT, the 12 mg result is roughly double the STEP-2 semaglutide result.

Side-effect profile cross-trial

GI adverse effects dominate both drugs:

  • Wegovy nausea: approximately 44% in pooled adult obesity trials (Section 6.1 of the prescribing information)[11]. Diarrhea, vomiting, and constipation also above 20%.
  • Retatrutide TRIUMPH-1 nausea: approximately 42.4% on 12 mg vs about 14.8% on placebo per Lilly topline[1]. Detailed AE tables (vomiting, diarrhea, constipation, discontinuation, serious adverse events) are reported in the full NEJM paper; its abstract lists gastrointestinal events as the most common[12].
  • Heart rate: Wegovy raises mean resting heart rate by 1 to 4 bpm per label Section 5.9; about 26% of treated adults had a peak heart-rate increase of 20 bpm or more at some visit during STEP-1/3/5 vs 16% on placebo[11]. See our Wegovy heart palpitations evidence article for the full safety framing. The TRIUMPH-1 abstract does not report heart-rate changes; see the full NEJM paper[12].
  • Retatrutide-specific signal: the Phase 2 trial (Jastreboff 2023)[3] reported a dose-dependent dysesthesia/paresthesia signal not described in semaglutide trials. Patients with peripheral neuropathy history should discuss this with their prescriber once retatrutide is available.

Cardiovascular outcomes — Wegovy has SELECT; retatrutide TRIUMPH-Outcomes pending

Wegovy has a proven cardiovascular benefit. SELECT (Lincoff 2023 NEJM, PMID 37952131) randomized 17,604 adults with obesity and pre-existing cardiovascular disease but without diabetes to semaglutide 2.4 mg vs placebo, with mean follow-up 39.8 months[9]. Primary result: 20% relative reduction in major adverse cardiovascular events (cardiovascular death, non-fatal MI, non-fatal stroke); HR 0.80, 95% CI 0.72 to 0.90. This result drove the March 2024 FDA label expansion to a cardiovascular-event-reduction indication.

Retatrutide cardiovascular outcomes data do not yet exist. TRIUMPH-Outcomes (NCT06383390), the retatrutide cardiovascular and kidney outcomes trial, is ongoing[15]; TRIUMPH-3, in adults with obesity and established cardiovascular disease, is a weight-loss trial rather than an outcomes trial[4]. Until TRIUMPH-Outcomes reads out, Wegovy is the only drug in this class with proven hard cardiovascular-event benefit in adults with obesity. For most patients with established cardiovascular disease, that fact alone tilts the decision toward an approved-and-CVOT-proven Wegovy regimen now, with retatrutide reserved as a future option pending TRIUMPH-Outcomes and FDA approval.

Weight maintenance evidence on semaglutide also has a published trial: STEP-4 (Rubino 2021 JAMA, PMID 33755728)[8] randomized 803 patients who had completed a 20-week semaglutide run-in to continued semaglutide vs placebo through week 68; continued treatment produced an additional -7.9% TBWL vs +6.9% regain on placebo. Retatrutide maintenance data have not been published.

Real-world delivery rate caveat

Real-world TBWL across the GLP-1 class consistently runs well below pivotal-trial means. Gasoyan 2024 JAMA Network Open (PMID 39269703)[10] analyzed 3,389 adults in a Cleveland Clinic cohort treated with injectable semaglutide or liraglutide and reported a mean 1-year weight loss of 5.9% among patients treated for obesity (semaglutide or liraglutide) — compared with 14.9% at 68 weeks in STEP-1[6], or about 40% of the pivotal-trial mean. Patients on semaglutide for obesity who kept continuous coverage averaged 12.9%. Among patients with persistent medication coverage, the mean was 5.5%; among those with under 90 days coverage, only 1.8%.

Applied to retatrutide 12 mg, a realistic real-world expectation at 80 weeks is in the roughly 9 to 17% TBWL range for the average patient, with the most adherent subset approaching the upper end. The trial-vs-real-world gap is driven by missed doses, supply pauses, side-effect-driven discontinuations, and the absence of trial-level lifestyle counseling. The retatrutide cross-trial advantage over Wegovy will likely persist in real-world use, but the absolute magnitudes will be smaller than either trial reported.

Cost + availability today

Wegovy: published US WAC list price is approximately $1,349 per 28-day supply. Novo Nordisk operates NovoCare direct-pay tiers with a $349 self-pay rate for the pen ($199 for a new patient's first two months), a $399 high-dose pen tier, and a $149 oral pill tier where applicable. Commercial-insurance coverage commonly applies with prior authorization keyed to BMI 30+ or BMI 27+ with a comorbidity. The new cardiovascular-event-reduction indication has broadened payer coverage for adults with established cardiovascular disease.

Retatrutide: not commercially available. No FDA approval, no published list price, and no Lilly-operated direct-pay portal. Compounded retatrutide sits in a regulatory gray zone with no FDA approval to anchor §503A pharmacy compounding, no presence on the FDA Drug Shortage list, and no USP monograph. This is not a stable supply path the patient should rely on. For more detail on the approval pathway and pricing mechanisms, see our companion analysis of what will determine retatrutide pricing once approved.

Practical takeaway

For most patients in October 2026, the decision is between an FDA-approved, CVOT-proven, widely-available drug (Wegovy) today, and an investigational triple agonist with larger trial-magnitude weight loss (retatrutide) sometime in 2027 or later. The right answer depends on individual context — cardiovascular history, BMI category, coverage, prior GLP-1 experience, side-effect tolerance — and that decision belongs with the prescriber. The cross-trial magnitude advantage of retatrutide is real but is not RCT-grade evidence, and the real-world delivery gap will compress the difference. Wegovy today is not a placeholder; it is a drug with a proven 20% reduction in major adverse cardiovascular events[9] and a stable FDA label backed by four years of real-world use. For broader cross-class context see our retatrutide vs tirzepatide head-to-head evidence article.

Cross-trial magnitude chart

Magnitude comparison

Mean total body-weight reduction at trial endpoint — cross-trial comparison of retatrutide TRIUMPH-1 dose-response (Phase 3 pivotal) and Phase 2 (Jastreboff 2023) versus FDA-approved Wegovy (semaglutide 2.4 mg, STEP-1). No head-to-head RCT exists. Values are % TBWL from each trial's primary endpoint. Sources: TRIUMPH-1 (NEJM 2026, PMID 42814954; the 104-week extension figure is from Lilly's May 2026 press release); Jastreboff 2023 NEJM PMID 37366315; STEP-1 NEJM PMID 33567185.[1][3][6][12]

  • Placebo (STEP-1, 68 wk)2.4 % TBWL
  • Wegovy - semaglutide 2.4 mg (STEP-1, 68 wk)14.9 % TBWL
    FDA-approved (2021)
  • Retatrutide 4 mg (TRIUMPH-1, 80 wk)17.6 % TBWL
    starter dose exceeds Wegovy ceiling
  • Retatrutide 12 mg (Phase 2, Jastreboff 2023, 48 wk)24.2 % TBWL
  • Retatrutide 9 mg (TRIUMPH-1, 80 wk)23.7 % TBWL
  • Retatrutide 12 mg (TRIUMPH-1, 80 wk)25.0 % TBWL
    primary endpoint (ITT); ~1.7x Wegovy
  • Retatrutide 12 mg (TRIUMPH-1 ext., BMI 35+, 104 wk)30.3 % TBWL
    Lilly press release; approaches bariatric-surgery magnitude
Mean total body-weight reduction at trial endpoint — cross-trial comparison of retatrutide TRIUMPH-1 dose-response (Phase 3 pivotal) and Phase 2 (Jastreboff 2023) versus FDA-approved Wegovy (semaglutide 2.4 mg, STEP-1). No head-to-head RCT exists. Values are % TBWL from each trial's primary endpoint. Sources: TRIUMPH-1 (NEJM 2026, PMID 42814954; the 104-week extension figure is from Lilly's May 2026 press release); Jastreboff 2023 NEJM PMID 37366315; STEP-1 NEJM PMID 33567185.

Further reading

Our reviews

Providers that offer semaglutide

Telehealth providers we’ve reviewed. Each opens our full, independent review.

We may earn a commission from featured partners. Learn more

See the full ranking →

Frequently Asked Questions

No. Wegovy (semaglutide 2.4 mg) has been FDA-approved for chronic weight management since June 2021, and in March 2024 the FDA added a cardiovascular-event-reduction indication based on SELECT. Retatrutide is investigational. Its TRIUMPH-1 (NEJM) and TRIUMPH-2 (Lancet) Phase 3 trials were published in 2026, and Eli Lilly's August 2026 earnings release says it plans to submit a Biologics License Application to the FDA in the first quarter of 2027. US commercial availability depends on the FDA's review after that submission, so it will not be available in 2026.
On a cross-trial basis (no head-to-head RCT exists), retatrutide 12 mg at 80 weeks in TRIUMPH-1 produced -25.0% mean total body-weight reduction in the published intention-to-treat analysis, while semaglutide 2.4 mg at 68 weeks in STEP-1 produced -14.9%. That is roughly 1.7 times the Wegovy magnitude. Even the retatrutide 4 mg dose (-17.6% at 80 weeks) exceeds the Wegovy 2.4 mg STEP-1 result. The trial populations and durations differ, so the comparison is indirect, but every retatrutide TRIUMPH-1 dose tier exceeds Wegovy's STEP-1 endpoint.
GI side effects are common on both drugs. The Wegovy label Section 6.1 reports nausea in 44% of patients in pooled adult obesity trials. Lilly's TRIUMPH-1 topline reported nausea in roughly 42.4% on retatrutide 12 mg vs about 14.8% on placebo. Wegovy is associated with a small mean resting heart-rate increase of 1 to 4 bpm. Full TRIUMPH-1 adverse-event data are reported in the NEJM paper (2026). Patients with peripheral neuropathy history should also know the retatrutide Phase 2 trial reported a dose-dependent dysesthesia/paresthesia signal not seen in Wegovy trials.
Not yet proven. Wegovy has SELECT (Lincoff 2023 NEJM, n=17,604, mean follow-up 39.8 months), which showed a 20% relative reduction in major adverse cardiovascular events in adults with obesity and pre-existing cardiovascular disease but no diabetes (HR 0.80, 95% CI 0.72 to 0.90). The retatrutide cardiovascular outcomes trial (TRIUMPH-Outcomes) is ongoing and has not reported. Until it reads out, Wegovy is the only drug in this class with a proven hard-cardiovascular-event benefit in adults with obesity.
Mechanism. Wegovy is a single-class GLP-1 receptor agonist (semaglutide). Retatrutide engages three receptors: GLP-1, GIP, and glucagon. The GLP-1 component drives satiety and slowed gastric emptying. The GIP component adds insulin-sensitizing and adipose-metabolic effects (the same axis tirzepatide uses). The glucagon receptor component additionally drives hepatic energy expenditure and lipolysis. Together, the triple-agonist mechanism appears to push mean weight loss into a magnitude band historically associated with bariatric surgery, though the full mechanism-to-magnitude attribution remains an active area of research.
Probably not for the typical patient. Gasoyan et al. 2024 (JAMA Network Open, PMID 39269703) analyzed 3,389 real-world adults on injectable semaglutide or liraglutide and found mean 1-year weight reduction of 5.9% in patients treated for obesity (semaglutide or liraglutide), vs 14.9% at 68 weeks in STEP-1 — about 40% of the pivotal-trial mean. Applied to retatrutide 12 mg, a realistic real-world expectation at 80 weeks is closer to 9 to 17% TBWL for the average patient, with the most adherent subset reaching the high end. The trial-vs-real-world gap is driven by missed doses, supply pauses, side-effect-driven discontinuations, and the absence of trial-level lifestyle counseling.
Wegovy's published US list price (WAC) is approximately $1,349 per 28-day supply. Novo Nordisk operates NovoCare Pharmacy direct-pay tiers: a $349 self-pay rate for the pen ($199 for a new patient's first two months), a $399 high-dose pen tier, and a $149 oral pill tier where applicable. Retatrutide has no commercial price because it is not FDA-approved and no brand has launched. Compounded retatrutide sits in a regulatory gray zone (no FDA approval to anchor §503A compounding, not on the FDA Drug Shortage List, no USP monograph) and is not a stable supply path the patient should rely on.
Almost always no — that decision belongs with your prescriber. The conservative timeline puts retatrutide commercial availability in 2027 or later. Waiting 12 to 24 months with untreated obesity carries its own cardiovascular and metabolic risks. Wegovy is FDA-approved today, has a cardiovascular-event-reduction indication, is broadly available, and has 4+ years of real-world safety data. For most patients the right path is start on an approved therapy now and discuss switching to retatrutide on label day-one if and when it is approved and your prescriber considers it appropriate.
No. There is no head-to-head randomized controlled trial of retatrutide vs semaglutide 2.4 mg. Every comparison in this article is cross-trial: TRIUMPH-1 (retatrutide, n=2,339, 80 weeks) and STEP-1 (Wegovy, n=1,961, 68 weeks) enrolled different populations under different protocols. Baseline characteristics differ (BMI, age, sex distribution), endpoints differ in timing, and the lifestyle interventions differ. The 1.7x multiplier is informative but not RCT-grade evidence. A true RCT comparison would require Lilly or an independent group to randomize patients to both drugs in the same trial — none has been announced.
Not through any legal, approved pathway today. Retatrutide is investigational and not FDA-approved, so a clinician cannot prescribe it and a pharmacy cannot fill it outside of an active clinical trial. If retatrutide is approved (conservative timing is 2027 or later), moving from Wegovy would be a decision to make with your prescriber and would typically involve a fresh dose-escalation period rather than a direct milligram-for-milligram swap. Be wary of 'research-grade' or gray-market retatrutide marketed as a switch option — those products have unverified identity, potency, and sterility, and are not a safe or legal way to come off Wegovy.
Because retatrutide is investigational, there is no FDA-approved label defining its contraindications yet, but its GLP-1/GIP/glucagon mechanism means the incretin class-wide cautions are expected to apply. That generally includes people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), and pregnancy is not an appropriate time for weight-loss pharmacotherapy. Trial eligibility criteria have also excluded people with a history of pancreatitis, significant GI disease, or certain cardiovascular conditions. Anyone weighing retatrutide should have suitability assessed by a clinician rather than self-selecting or sourcing it independently.
Among FDA-approved options, tirzepatide (Zepbound) is the stronger approved drug — SURMOUNT-1 produced roughly -20.9% mean weight loss at 72 weeks vs Wegovy's ~-14.9% in STEP-1. Retatrutide's -25.0% in TRIUMPH-1 is numerically larger still, but it is investigational and cannot be legally obtained yet, so it is a pipeline hope rather than an available choice. If you have plateaued on Wegovy and want a stronger approved therapy now, the realistic conversation with your prescriber is about tirzepatide (Zepbound), not retatrutide.

References

  1. 1.Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. (TRIUMPH-1 pivotal Phase 3 results presented at the American Diabetes Association 86th Scientific Sessions, May 2026.) PR Newswire (Eli Lilly Investor Release), May 2026. 2026. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html
  2. 2.Eli Lilly and Company. A Study of Retatrutide (LY3437943) in Adult Participants With Obesity (TRIUMPH-1). ClinicalTrials.gov NCT05929066. 2026. https://clinicaltrials.gov/study/NCT05929066
  3. 3.Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023. PMID: 37366315.
  4. 4.Giblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, Wu Q, Lalonde A, Ahmad N, Bethel MA. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism. 2026. PMID: 41090431.
  5. 5.Pearson MJ, Willency JA, Lin Y, Abadi A, Hartman ML, Coskun T, Ruotolo G, Duffin KL. Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes. J Clin Endocrinol Metab. 2026. PMID: 42135195.
  6. 6.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, et al.; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
  7. 7.Davies M, Faerch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; STEP 2 Study Group. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, Phase 3 trial. Lancet. 2021. PMID: 33667417.
  8. 8.Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021. PMID: 33755728.
  9. 9.Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, et al.; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. PMID: 37952131.
  10. 10.Gasoyan H, Pfoh ER, Schulte R, Le P, Rothberg MB. One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice. JAMA Netw Open. 2024. PMID: 39269703.
  11. 11.Novo Nordisk Inc. WEGOVY (semaglutide) injection and tablets — US Prescribing Information (Sections 1 Indications, 5 Warnings and Precautions, 6.1 Clinical Trials Experience). Revised May 2026. DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  12. 12.Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, et al.; TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. PMID: 42814954.
  13. 13.Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. PMID: 42810372.
  14. 14.Eli Lilly and Company. Lilly reports second-quarter 2026 financial results (Form 8-K exhibit). U.S. Securities and Exchange Commission. 2026. https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm
  15. 15.Eli Lilly and Company. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) (NCT06383390). ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT06383390

Retatrutide Approval & Access Timeline: TRIUMPH Results, 2027 FDA Filing, No Compounding

Retatrutide is not FDA-approved. Lilly plans to file in the first quarter of 2027, so it will not be prescribable in 2026. TRIUMPH-1 showed up to 25.0% weight loss at 80 weeks, and it cannot legally be compounded under 503A or 503B.

12 min read

Retatrutide Before and After: What TRIUMPH-1 Actually Showed

TRIUMPH-1 (n=2,339; NEJM 2026) reported -25.0% mean weight loss at 80 weeks on retatrutide 12 mg (intention-to-treat; Lilly's press release cited -28.3% on-treatment). Honest framing of transformation magnitude, dose-response, and real-world expectations.

12 min read

Retatrutide Side Effects: Comprehensive Phase 3 Evidence Review

TRIUMPH-1 pivotal phase 3 retatrutide adverse-event review: GI rates, a dysesthesia signal (12.5% vs 0.9% placebo) also seen with high-dose semaglutide, 11.3% discontinuation, and head-to-head AE comparison with Wegovy, Zepbound, and Foundayo.

15 min read

Retatrutide TRIUMPH Phase 3: Latest Pipeline Update

In the TRIUMPH-1 phase 3 trial, Lilly's retatrutide produced up to 25.0% weight loss at 80 weeks, and 18.8% in people with type 2 diabetes in TRIUMPH-2. Lilly plans to file with the FDA in Q1 2027. Open safety questions and the access timeline are covered.

11 min read

Retatrutide vs Foundayo (orforglipron) — TRIUMPH-1 vs ATTAIN-1 cross-trial evidence

Retatrutide −25.0% TBWL at 12 mg / 80 wk (TRIUMPH-1, NEJM 2026) vs Foundayo (orforglipron) ~−11% at 17.2 mg / 72 wk (ATTAIN-1), roughly 2.2× on a cross-trial basis. Both are Eli Lilly molecules; Foundayo is FDA-approved (April 2026), retatrutide is investigational.

12 min read

Retatrutide vs tirzepatide — TRIUMPH-1 vs SURMOUNT-1 head-to-head evidence

Retatrutide -25.0% TBWL at 12 mg / 80 wk (TRIUMPH-1, NEJM 2026) vs tirzepatide -20.9% at 15 mg / 72 wk (SURMOUNT-1), about 4 points on a cross-trial basis. Nausea, a dysesthesia signal, and discontinuation run higher, and retatrutide is not FDA-approved.

11 min read

Where to get semaglutide (Ozempic / Wegovy) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

7.1

AgelessRx

Longevity-focused GLP-1 care with microdosing and brand-name options

Read full review →

From $139/mo

4-month plan rate

Get started →
7.2

HumeCare+

GLP-1 weight loss with real-time body-composition tracking to protect muscle

Read full review →

From $199/mo

Get started →
8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Read full review →

From $59/mo

+ required membership

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →